scholarly journals Comparative Rates of Serious Infections Among Patients With Systemic Lupus Erythematosus Receiving Immunosuppressive Medications

2017 ◽  
Vol 69 (2) ◽  
pp. 387-397 ◽  
Author(s):  
Candace H. Feldman ◽  
Francisco M. Marty ◽  
Wolfgang C. Winkelmayer ◽  
Hongshu Guan ◽  
Jessica M. Franklin ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Lupus Erythematosus ◽  
Systemic Lupus ◽  
Immunosuppressive Medications ◽  
Serious Infections

scholarly journals 181 Associated factors to the presence of serious infections in a large cohort of juvenile-onset systemic lupus erythematosus

2019 ◽  
Author(s):  
Jose Maria Pego Reigosa ◽  
Vicenç Torrente-Segarra ◽  
Victor Del Campo Perez ◽  
Tarek Salman-Monte ◽  
Javier Narváez-García ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Lupus Erythematosus ◽  
Associated Factors ◽  
Large Cohort ◽  
Systemic Lupus ◽  
Juvenile Onset ◽  
Serious Infections ◽  
Onset Systemic Lupus Erythematosus

scholarly journals Associated factors to serious infections in a large cohort of juvenile-onset systemic lupus erythematosus from Lupus Registry (RELESSER).

2020 ◽  
Vol 50 (4) ◽  
pp. 657-662 ◽  
Author(s):  
Vicenç Torrente-Segarra ◽  
Tarek C. Salman-Monte ◽  
Íñigo Rúa-Figueroa ◽  
Víctor del Campo ◽  
Francisco Javier López-Longo ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Lupus Erythematosus ◽  
Associated Factors ◽  
Large Cohort ◽  
Systemic Lupus ◽  
Juvenile Onset ◽  
Serious Infections ◽  
Onset Systemic Lupus Erythematosus

Factors predictive of serious infections over time in systemic lupus erythematosus patients: data from a multi-ethnic, multi-national, Latin American lupus cohort

Lupus ◽  
2019 ◽  
Vol 28 (9) ◽  
pp. 1101-1110 ◽  
Author(s):  
V R Pimentel-Quiroz ◽  
M F Ugarte-Gil ◽  
GB Harvey ◽  
D Wojdyla ◽  
G J Pons-Estel ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Disease Activity ◽  
Latin American ◽  
Lupus Erythematosus ◽  
Clinical Manifestations ◽  
Hazard Ratio ◽  
Systemic Lupus ◽  
Serious Infections ◽  
Damage Accrual ◽  
Over Time

Aim The aim of this study was to identify factors predictive of serious infections over time in patients with systemic lupus erythematosus (SLE). Methods A multi-ethnic, multi-national Latin American SLE cohort was studied. Serious infection was defined as one that required hospitalization, occurred during a hospitalization or led to death. Potential predictors included were sociodemographic factors, clinical manifestations (per organ involved, lymphopenia and leukopenia, independently) and previous infections at baseline. Disease activity (SLEDAI), damage (SLICC/ACR Damage Index), non-serious infections, glucocorticoids, antimalarials (users and non-users), and immunosuppressive drugs use; the last six variables were examined as time-dependent covariates. Cox regression models were used to evaluate the predictors of serious infections using a backward elimination procedure. Univariable and multivariable analyses were performed. Results Of the 1243 patients included, 1116 (89.8%) were female. The median (interquartile range) age at diagnosis and follow-up time were 27 (20–37) years and 47.8 (17.9–68.6) months, respectively. The incidence rate of serious infections was 3.8 cases per 100 person-years. Antimalarial use (hazard ratio: 0.69; 95% confidence interval (CI): 0.48–0.99; p = 0.0440) was protective, while doses of prednisone >15 and ≤60 mg/day (hazard ratio: 4.18; 95 %CI: 1.69–10.31; p = 0.0019) and >60 mg/day (hazard ratio: 4.71; 95% CI: 1.35–16.49; p = 0.0153), use of methylprednisolone pulses (hazard ratio: 1.53; 95% CI: 1.10–2.13; p = 0.0124), increase in disease activity (hazard ratio: 1.03; 95% CI: 1.01–1.04; p = 0.0016) and damage accrual (hazard ratio: 1.22; 95% CI: 1.11–1.34; p < 0.0001) were predictive factors of serious infections. Conclusions Over time, prednisone doses higher than 15 mg/day, use of methylprednisolone pulses, increase in disease activity and damage accrual were predictive of infections, whereas antimalarial use was protective against them in SLE patients.

Serious infections in systemic lupus erythematosus with a focus on pneumococcal infections

Lupus ◽  
2014 ◽  
Vol 23 (14) ◽  
pp. 1512-1516 ◽  
Author(s):  
R K M A C Luijten ◽  
B V J Cuppen ◽  
J W J Bijlsma ◽  
R H W M Derksen
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Lupus Erythematosus ◽  
Pneumococcal Infections ◽  
Systemic Lupus ◽  
Serious Infections

scholarly journals Sociodemographics and epidemiology of serious infections requiring hospitalization among adults with systemic lupus erythematosus and lupus nephritis, 2000 to 2006

2014 ◽  
Vol 16 (Suppl 1) ◽  
pp. A37
Author(s):  
Candace H Feldman ◽  
Linda T Hiraki ◽  
Wolfgang Winkelmayer ◽  
Francisco M Marty ◽  
Jessica M Franklin ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Lupus Nephritis ◽  
Lupus Erythematosus ◽  
Systemic Lupus ◽  
Serious Infections

Serious infections in British patients with systemic lupus erythematosus: hospitalisations and mortality

Lupus ◽  
2009 ◽  
Vol 18 (8) ◽  
pp. 682-689 ◽  
Author(s):  
F Goldblatt ◽  
S Chambers ◽  
A Rahman ◽  
DA Isenberg
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Lupus Erythematosus ◽  
Systemic Lupus ◽  
Serious Infections

scholarly journals Trends in actual medication use for child-onset systemic lupus erythematosus using the Japanese health insurance database 2009–18

2021 ◽  
Author(s):  
Takayuki Kishi ◽  
Ryoko Sakai ◽  
Yumi Tani ◽  
Satoru Nagata ◽  
Yasuhiro Katsumata ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Lupus Erythematosus ◽  
Oral Prednisolone ◽  
Systemic Lupus ◽  
Maximum Daily Dose ◽  
Immunosuppressive Medications ◽  
Daily Dose ◽  
Insurance Database ◽  
Over Time ◽  
Onset Systemic Lupus Erythematosus

ABSTRACT Objectives Immunosuppressive therapy is the mainstay of treatment for child-onset systemic lupus erythematosus (cSLE). Since epidemiological data on Japanese cSLE patients are not available, we evaluated the trends in how treatment choices have changed over time in Japan. Methods Using the Japanese health insurance database provided by Medical Data Vision Co., Ltd, we identified cSLE patients and evaluated changes in the use of corticosteroids and immunosuppressive medications and maximum daily doses of prednisolone from 2009 to 2018. Results Of 182 cSLE patients, 86% were female, and the median age was 14 years. Oral prednisolone was used in more than 97% of cSLE patients during the study period, and the median of the maximum daily dose in each patient decreased over time. Intravenous cyclophosphamide was used less frequently after 2016, while mycophenolate mofetil and hydroxychloroquine were used frequently after 2016. The use of mizoribine reduced after 2014, whereas the other immunosuppressive medications showed no significant change over time; the use of biological agents was very limited. Conclusions Oral prednisolone was the mainstay of treatment for cSLE, and the maximum daily dose has reduced over the past decade. The most frequently prescribed immunosuppressive therapy has shifted to mycophenolate mofetil over time.

scholarly journals Serious Infections Among Adult Medicaid Beneficiaries With Systemic Lupus Erythematosus and Lupus Nephritis

2015 ◽  
Vol 67 (6) ◽  
pp. 1577-1585 ◽  
Author(s):  
Candace H. Feldman ◽  
Linda T. Hiraki ◽  
Wolfgang C. Winkelmayer ◽  
Francisco M. Marty ◽  
Jessica M. Franklin ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Lupus Nephritis ◽  
Lupus Erythematosus ◽  
Systemic Lupus ◽  
Serious Infections ◽  
Medicaid Beneficiaries
Sign in / Sign up

Export Citation Format

Share Document